Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial)

NCT06529406 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT06529406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06529406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod (COAST: CD20 and Ozanimod Sequencing Trial)
Lead sponsor
University of Colorado, Denver
Phase
Phase 4
Overall status
Recruiting
Start date
July 29, 2024
Completion date
August 1, 2029
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis